Jasper Therapeutics presents data from SPOTLIGHT Phase 1b/2a study
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
02-08-2025
- Yahoo
Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients
Astria Therapeutics Inc. (NASDAQ:ATXS) is one of the stocks under $10 to buy now. Earlier on June 13, Astria Therapeutics announced positive initial results from the ALPHA-SOLAR long-term open-label trial of navenibart (STAR-0215) in hereditary angioedema/HAE patients. These findings were presented at the European Academy of Allergy and Clinical Immunology/EAACI Annual Congress. The trial showed an overall reduction in the monthly HAE attack rate, with a 92% mean and 97% median reduction. These results support the potential for every three-month and every six-month dosing regimens for navenibart, as well as its favorable safety and tolerability profile. These initial results from ALPHA-SOLAR are consistent with the 'best-in-class' profile observed in the earlier ALPHA-STAR Phase 1b/2 trial. A closeup of pills in a pharmacy, representing the high quality medications of the company. The ALPHA-SOLAR trial is a long-term, open-label study designed to assess the safety and efficacy of navenibart in adults with HAE Type 1 or 2. All 16 target enrollment participants from the Phase 1b/2 ALPHA-STAR trial opted to enroll in ALPHA-SOLAR. Patients from ALPHA-STAR Cohorts 1 and 2 joined Arm A, while Cohort 3 patients joined Arm B. Astria Therapeutics Inc. (NASDAQ:ATXS) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for allergic and immunological diseases in the US. While we acknowledge the potential of ATXS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Yahoo
01-08-2025
- Yahoo
Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients
Astria Therapeutics Inc. (NASDAQ:ATXS) is one of the stocks under $10 to buy now. Earlier on June 13, Astria Therapeutics announced positive initial results from the ALPHA-SOLAR long-term open-label trial of navenibart (STAR-0215) in hereditary angioedema/HAE patients. These findings were presented at the European Academy of Allergy and Clinical Immunology/EAACI Annual Congress. The trial showed an overall reduction in the monthly HAE attack rate, with a 92% mean and 97% median reduction. These results support the potential for every three-month and every six-month dosing regimens for navenibart, as well as its favorable safety and tolerability profile. These initial results from ALPHA-SOLAR are consistent with the 'best-in-class' profile observed in the earlier ALPHA-STAR Phase 1b/2 trial. A closeup of pills in a pharmacy, representing the high quality medications of the company. The ALPHA-SOLAR trial is a long-term, open-label study designed to assess the safety and efficacy of navenibart in adults with HAE Type 1 or 2. All 16 target enrollment participants from the Phase 1b/2 ALPHA-STAR trial opted to enroll in ALPHA-SOLAR. Patients from ALPHA-STAR Cohorts 1 and 2 joined Arm A, while Cohort 3 patients joined Arm B. Astria Therapeutics Inc. (NASDAQ:ATXS) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for allergic and immunological diseases in the US. While we acknowledge the potential of ATXS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
17-07-2025
- Yahoo
EAACI Leadership Reflects on Record-Breaking Congress 2025: A Pivotal Moment for Allergy and Immunology
Entrance of the EAACI Congress 2025, SEC in Glasgow ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- With over 7,600 delegates in attendance, EAACI Congress 2025 made headlines not just for its scale but for the powerful message delivered by its leadership. Now, one month after the Congress concluded in Glasgow, EAACI's top figures are sharing their reflections on what they call a turning point for the field. Held from 13–16 June at the Scottish Event Campus, the event championed the theme: 'Breaking Boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future.' 'This year's Congress was a turning point,' said Prof. Maria Torres, EAACI President. 'We are entering an era where scientific innovation, equity in care, and environmental health must move forward together.' The programme featured over 250 hours of lectures, workshops, and symposia, covering groundbreaking advances in drug allergy, T2 inflammation, paediatric asthma, and hereditary angioedema. The Presidential Symposium tackled antimicrobial resistance through a One Health lens, while a timely session on climate change and insect allergy drew global attention to ecological impacts on patient care. Far beyond the walls of the SEC, the EAACI Congress 2025 activated the entire city with initiatives that brought science to the streets. The Clinical Village at the Glasgow Science Centre welcomed the public for hands-on allergy education, while the Beat Allergy Walk & Run raised funds for the Glasgow Children's Hospital Charity, reinforcing EAACI's commitment to social impact and community engagement. 'The spirit of collaboration we witnessed in Glasgow was extraordinary,' said Prof. André Moreira, EAACI Vice President Congresses. 'This energy is now translating into real-world initiatives and global partnerships.' The Congress also highlighted EAACI's dedication to mentorship, digital health innovation, and amplifying patient's voices. The countdown for the EAACI Congress 2026 in Istanbul has officially begun, but you won't have to wait until then to dive back into cutting-edge science. From focused meetings to hands-on courses, EAACI has a packed calendar to keep you inspired all year long. Check out what's coming next at About EAACIThe European Academy of Allergy and Clinical Immunology (EAACI) is Europe's largest professional association in the field, committed to advancing research and care for those affected by allergic diseases. Learn more: Contact: communications@ | +41 44 205 55 33 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
